Therefore, when radiotherapy is combined with immune checkpoint inhibitors (such as anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA4 antibody), T cell activity directed against tumor cells can be increased. This evidence concerns the gene CTLA4 and neoplasm.